Switzerland · Delayed Price · Currency is CHF Molecular Partners AG Earnings Call Transcripts
Fiscal Year 2026
-
MP0712, a DLL3-targeting radiotherapeutic, showed strong tumor uptake and favorable biodistribution in SCLC patients, with healthy organs remaining within safety limits. The phase I/II trial is open, with safety and early efficacy data expected in 2024, and plans for dose escalation and future expansion to other radionuclides and indications.
-
The presentation highlighted renewed optimism in biotech, with a strategic focus on radiotherapy and the MP0712 program. Early clinical data show promising tumor targeting and safety, with key updates expected throughout the year.
Fiscal Year 2025
-
MP0712, a DLL3-targeted alpha therapy, showed promising preclinical and first-in-human imaging results, supporting rapid advancement to a U.S. phase I trial in small cell lung cancer. The program leverages unique half-life engineering and aims for accelerated approval, with expansion to other indications planned.
-
The panel highlighted progress on radiotherapy and T-Cell Engager DARPin platforms, with MP0712 entering phase I for small cell lung cancer and MP0533 showing improved responses in AML after protocol adjustments. Lead-212 supply is secured via Orano Med, and next-gen Switch-DARPins are advancing toward clinical development.
-
The conference highlighted advances in DARPin-based oncology programs, including radiopharmaceuticals and T cell engagers. Key updates include expanded collaboration with Orano Med, phase I entry for DLL3, and promising AML data, with further clinical results expected in 2024.
-
The company is advancing a diverse pipeline of DARPin-based therapies, with imminent clinical entry for its lead radiopharma candidate in small cell lung cancer and promising early results from its multi-specific T-cell engager for AML. Strategic partnerships and global regulatory planning underpin its growth, with key data updates expected before year-end.
-
The session highlighted progress in radiotherapy and immune cell engager platforms, with key clinical readouts expected in 2024. Lead programs target DLL3 in small cell lung cancer and AML, supported by strong partnerships and a solid financial position.
Fiscal Year 2024
-
Advanced clinical pipeline with MP0712 (DLL3) entering trials and MP0533 in AML showing improved efficacy after dosing optimization. Expanded Orano Med partnership secures isotope supply, and a CHF 20 million raise extends cash runway into 2027.
-
Advanced MP0533, Radio-DARPin, and Switch-DARPin programs, with protocol amendments to improve MP0533 exposure and a strong cash position extending runway into 2027. Initial clinical data for MP0712 expected in H2 2025, and preclinical Switch-DARPin data due H2 2024.
-
DARPins enable high-specificity radiopharmaceuticals with deep tissue penetration and optimized tumor-to-kidney ratios. The pipeline features partnerships with Novartis and Orano Med, with MP0712 targeting DLL3 in small cell lung cancer and first-in-human studies planned for 2025.